[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-brain-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-brain-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,70,111,232,252,281,307,331,354,374,396,415],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100324915","phase-1-panitumumab-irdye800-in-diagnosing-participants-with-malignant-glioma-undergoing-surgery-100324915",false,"NCT03510208","Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery","Phase I\u002FII, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures","Inclusion Criteria:\n\n1\\) One of the following:\n\n1. Cohorts 1, 2, and 3: Participants with suspected or confirmed diagnosis of glioblastoma\n2. Cohort 4: Participants with suspected or confirmed diagnosis of vestibular schwannoma\n\n   2.) Planned surgical removal of the tumor as part of standard of care. This may include participants postchemotherapy, post-radiation, and\u002For participants who have undergone diagnostic biopsy for their original diagnosis and are felt to be candidates for resection.\n\n   3\\) Participant age ≥ 18 years.\n\n   4\\) Participants or their designated advocates must be willing to and capable of providing informed consent and willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.\n\nExclusion Criteria:\n\n1. Received an investigational drug within 30 days prior to first dose of Panitumumab-IRDye800.\n2. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease as determined by PI; or unstable angina within 6 months prior to enrollment.\n3. History of infusion reactions to monoclonal antibody therapies\n4. Pregnant or breastfeeding.\n5. Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in males or greater than 460 ms in females).\n6. Any of the following lab values:\n\n   1. Platelet count \\\u003C 75,000\u002Fmm3\n   2. TSH ≥ 13 micro International Units\u002FmL.\n   3. Magnesium, potassium, or calcium \\\u003C each respective upper limit of normal\n   4. Serum creatinine \\> 1.5 times upper limit of normal\n7. Participants receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.\n8. Participants with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.\n9. Participants not deemed by PI to be appropriate candidates for optimal resection of tumor based on location, involvement of eloquent brain, satellite lesions, or other factors not specifically listed here.","ALL","18 Years",{"count":19,"type":20},46,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The phase I\u002FII trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.",[27,28],"Malignant Brain Neoplasm","Malignant Glioma","RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":33},"2018-05-16",{"date":37,"type":20},"2026-11",{"name":39,"class":40},"Stanford University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100576714","breathing-practice-for-brain-and-mental-health-in-cancer-and-neurodegenerative-diseases-100576714","NCT06788886","Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases","Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)","Inclusion Criteria:\n\n* STUDY 1: Participants must be physically fit enough to perform light exercise.\n* STUDY 1: Should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 1: Must have access to a smartphone or tablet.\n* STUDY 2: Participants must be physically fit enough to perform light exercise.\n* STUDY 2: Cancer patients may have prostate cancer, neuroendocrine tumor, or brain cancer in any stage.\n* STUDY 2: The main focus is on pairs of cancer patients and their respective caregivers, but individual cancer patients or individual caregivers are also acceptable.\n* STUDY 2: Participants should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 2: They also must have access to a smartphone or tablet.\n* STUDY 3: Participants must be physically fit enough to perform light exercise.\n* STUDY 3: The patient should have multiple sclerosis.\n* STUDY 3: Participants should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 3: They also must have access to a smartphone or tablet.\n\nExclusion Criteria:\n\n* STUDY 1: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants.\n* STUDY 1: Additionally, those with chronic medical conditions, including heart disease (coronary artery disease, congestive heart failure, hypertension, cardiac arrhythmia), chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, diabetes, sleep apnea, aneurysms, and neurological conditions (epilepsy, Alzheimer's disease, Huntington' disease, essential tremor and Parkinson disease) are excluded.\n* STUDY 1: Participants with psychiatric conditions such as psychosis, suicidality, bipolar disorder, major depression, and substance use disorders are excluded.\n* STUDY 1: Participants serving as caregivers for any of the aforementioned conditions and for other illnesses such as cancer or neurological disorders, are also excluded.\n* STUDY 1: Further exclusions apply to those with severe vision, hearing impairments, have a body mass index (BMI) over 30, and those who are pregnant.\n* STUDY 1: Those planning to become pregnant during the study period will be excluded.\n* STUDY 2: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants are excluded, as are those with chronic lung disease (chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis), aneurysms, and those who are pregnant.\n* STUDY 2: Those planning to become pregnant during the study period will be excluded.\n* STUDY 3: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants are excluded, as are those with chronic lung disease (chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis), aneurysms, and those who are pregnant.\n* STUDY 3: Those planning to become pregnant during the study period will be excluded.",true,"85 Years",{"count":52,"type":20},147,[54],"NA","This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers). The relationship between respiration, cardiovascular effects in the brain, mental health, and neurophysiological mechanisms are significant for patient populations facing complex health challenges, such as those with cancer and neurodegenerative disease, and their caregivers. By measuring oxygen delivery to brain tissues and cerebrospinal fluid flow, this trial may help researchers investigate the potential benefits of respiratory training for patients with MS and cancer and their caregivers.",[27,57,58,59,60],"Malignant Solid Neoplasm","Multiple Sclerosis","Neuroendocrine Tumor","Prostate Carcinoma","2026-06-08",{"date":63,"type":33},"2026-06-10",{"date":65,"type":33},"2025-02-05",{"date":67,"type":20},"2027-01-18",{"name":69,"class":40},"Mayo Clinic",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":41},"100348926","intravital-microscopy-in-human-solid-tumors-100348926","NCT03823144","Intravital Microscopy in Human Solid Tumors","Intravital Microscopy (IVM) in Human Solid Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2\n* Measurable tumor by direct visualization requiring surgical resection in the operating room (OR)\n* Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers. Tumors may be primary or metastatic\n* Subject must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent\n* Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein\n\nExclusion Criteria:\n\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations\n* Renal dysfunction as defined as a glomerular filtration rate (GFR) \\\u003C 45\n* Liver dysfunction as defined by Child-Pugh score \\> 5, or liver function test (LFT)'s 1.5 x above normal range\n* Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein\n* Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigators' opinion deems the patient unsuitable (e.g., abnormal electrocardiography \\[EKG\\], including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test)\n* Any condition that excludes surgical resection as the standard of care for the patient",{"count":78,"type":20},85,[54],"This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.",[82,83,57,84,85,86,87,88,89,90,91,92,93,94,27,95,96,97,98,99,100,101,102],"Solid Tumor, Adult","Clinical Stage IV Gastric Cancer AJCC v8","Metastatic Colorectal Carcinoma","Metastatic Gastric Carcinoma","Metastatic Primary Malignant Brain Neoplasm","Metastatic Sarcoma","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","Resectable Colorectal Carcinoma","Resectable Liver and Intrahepatic Bile Duct Carcinoma","Resectable Pancreatic Carcinoma","Resectable Sarcoma","Stage IV Colorectal Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Metastatic Liver Carcinoma","Metastatic Pancreatic Carcinoma","Resectable Brain Neoplasm","Resectable Breast Carcinoma","Resectable Gastric Carcinoma","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Pancreatic Cancer AJCC v8","2026-05-29",{"date":105,"type":33},"2026-06-02",{"date":107,"type":33},"2019-02-28",{"date":109,"type":20},"2027-09-30",{"name":69,"class":40},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100612878","social-health-activity-behaviors-and-quality-of-life-among-young-adult-cancer-survivors-100612878","NCT07259304","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors: A Longitudinal Study","Inclusion Criteria:\n\n* Diagnosed and\u002For treated with cancer between ages 18-39 at USC hospitals.\n* Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.\n* Must be within three months of a de novo cancer diagnosis at recruitment and on\u002Findicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.\n* Patients must have anticipated survival of \\>1-year at time of diagnosis.\n\nExclusion Criteria:\n\n* Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.\n* Primary language other than English or Spanish.\n* Inability to complete a survey and\u002For wear an accelerometer either per the patient or in consultation with the clinician's judgment.","39 Years",{"count":120,"type":20},250,"OBSERVATIONAL","This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.",[124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,27,57,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Central Nervous System Neoplasm","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Hodgkin Lymphoma","Malignant Bone Neoplasm","Malignant Testicular Neoplasm","Non-Hodgkin Lymphoma","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Stage I Cervical Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Differentiated Thyroid Gland Carcinoma AJCC v8","Stage I Ovarian Cancer AJCC v8","Stage I Thyroid Gland Medullary Carcinoma AJCC v8","Stage I Uterine Corpus Cancer AJCC v8","Stage IA Cervical Cancer AJCC v8","Stage IA Ovarian Cancer AJCC v8","Stage IA Uterine Corpus Cancer AJCC v8","Stage IA1 Cervical Cancer AJCC v8","Stage IA2 Cervical Cancer AJCC v8","Stage IB Cervical Cancer AJCC v8","Stage IB Ovarian Cancer AJCC v8","Stage IB Uterine Corpus Cancer AJCC v8","Stage IB1 Cervical Cancer AJCC v8","Stage IB2 Cervical Cancer AJCC v8","Stage IC Ovarian Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Differentiated Thyroid Gland Carcinoma AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Thyroid Gland Medullary Carcinoma AJCC v8","Stage II Uterine Corpus Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA Colorectal Cancer AJCC v8","Stage IIA Ovarian Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIB Colorectal Cancer AJCC v8","Stage IIB Ovarian Cancer AJCC v8","Stage IIC Colorectal Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage III Uterine Corpus Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","2026-05-26",{"date":224,"type":33},"2026-05-28",{"date":226,"type":33},"2021-11-24",{"date":228,"type":20},"2027-12-31",{"name":230,"class":40},"University of Southern California",2,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":41},"100567402","phase-2-an-investigational-scan-18f-dopa-petct-for-improving-the-clinical-management-of-brain-tumors-100567402","NCT06667726","An Investigational Scan (18F-DOPA PET\u002FCT) for Improving the Clinical Management of Brain Tumors","A Centralized Protocol Evaluating the Safety and Clinical Impact of Amino Acid Pet for Brain Tumors","Inclusion Criteria:\n\n* Age 18 and older\n* Diagnosis of a brain tumor\n* Indication for amino acid PET imaging, including presurgical evaluation, radiation planning, MR imaging indeterminate for progression versus treatment effect, or clinical need for enhanced monitoring\n* Ability to give appropriate consent or have an appropriate representative available to do so\n\nExclusion Criteria:\n\n* Patient is unable to undergo PET imaging\n* Persons who are pregnant or nursing",{"count":240,"type":20},47,[24],"This phase II trial studies how well the addition of 18F-DOPA (amino acid) positron emission tomography (PET)\u002Fcomputed tomography (CT) to standard of care (SOC) imaging can improve the clinical management of patients with brain tumors in over 50% of cases. PET is an imaging test that helps to measure the information about functions of tissues and organs within the body. A PET scan uses a radioactive drug (radiotracer) to show this activity. CT scan uses X-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. PET\u002FCT scans are hybrid scanners that combine both of the two modalities into a single scan. This allows images of both anatomy (CT) and function (PET) to be taken during the same scan. The 18F-DOPA PET\u002FCT scan is done with a very small amount of a radioactive tracer called FDOPA. The PET\u002FCT scan is then used to detect the location of tumors. Using the 18FDOPA-PET\u002FCT scan in addition to the SOC scan may improve the clinical management of patients with brain tumors.",[27],"2026-04-23",{"date":246,"type":33},"2026-04-28",{"date":248,"type":33},"2026-03-24",{"date":250,"type":20},"2028-05-31",{"name":69,"class":40},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":231},"100399013","cancer-genetic-testing-in-ethnic-populations-100399013","NCT04475640","Cancer Genetic Testing in Ethnic Populations","GEMINI - Cancer Genetic Testing in Ethnic Populations","Inclusion Criteria:\n\n* Patients at least 18 years of age\n* Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)\u002Fbrain, head\u002Fneck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management\u002Ftreatment; and patients receive genetic testing as described above\n* Self-identified as being from various ethnic populations including Hispanic\u002FLatino, Native American\u002FAlaskan, African American (including of African descent), Asian and other European populations\n* Blood collection is feasible (health, access and\u002For tolerability) for requested blood sample(s)\n* Individuals have agreed to participate and signed the study informed consent form\n\nExclusion Criteria:\n\n* Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent\n* Past or current history of hematological cancer (including leukemias, multiple myeloma)\n* All bone marrow transplants",{"count":260,"type":20},1800,[54],"This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.",[264,265,266,267,268,269,27,270,271,57,272],"Breast Carcinoma","Carcinoma of Unknown Primary","Central Nervous System Carcinoma","Digestive System Carcinoma","Genitourinary System Carcinoma","Head and Neck Carcinoma","Malignant Female Reproductive System Neoplasm","Malignant Musculoskeletal Neoplasm","Skin Carcinoma","2026-04-01",{"date":275,"type":33},"2026-04-02",{"date":277,"type":33},"2020-01-13",{"date":279,"type":20},"2028-10-15",{"name":69,"class":40},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100401653","phase-1-car-t-cells-after-lymphodepletion-for-the-treatment-of-il13r2-positive-recurrent-or-refractory-brain-tumors-in-children-100401653","NCT04510051","CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children","Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent\u002FRefractory Malignant Brain Tumors","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative.\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n* Karnofsky Performance Status (KPS) \\>= 60% except for loss of mobility due to disease involvement; e.g., confinement to a wheelchair due to spinal cord compression\n* Life expectancy \\> 4 weeks\n* Participant has a prior histologically-confirmed malignant brain neoplasm and has progressed after prior conventional therapy\n* Radiographic evidence of progression\u002Frecurrence of the measurable disease more than 12 weeks after the end of the initial conventional therapy (including initial radiation therapy)\n* City of Hope (COH) clinical pathology confirms IL13Ralpha2+ tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score \\>= 50)\n* If the participant has a shunt, it must be programmable and the participant must be able to tolerate the shunt being switched off for at least 2 consecutive days\n* Platelets \\>= 50,000\u002Fmm\\^3 (performed within 6 weeks of signing the main informed consent)\n* Total bilirubin =\\\u003C 2 X upper limit of normal (ULN) (unless has Gilbert's disease) (performed within 6 weeks of signing the main informed consent)\n* Aspartate transaminase (AST) =\\\u003C 2 x ULN (performed within 6 weeks of signing the main informed consent)\n* Alanine transferase (ALT) =\\\u003C 2 x ULN (performed within 6 weeks of signing the main informed consent)\n* Creatinine clearance of \\>= 75mL\u002Fmin\u002F1.73m\\^2 (performed within 6 weeks of signing the main informed consent)\n* Seronegative for human immunodeficiency virus (HIV) antigen (Ag)\u002Fantibody (Ab) combo, hepatitis C virus (HCV)\\* and active HBV (surface antigen negative) (performed within 6 weeks of signing the main informed consent)\n\n  * If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n* Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 6 weeks of signing the main informed consent)\n* Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.\n\n  * Childbearing potential defined as not being surgically sterilized (males and females) or have not been free, once initiated, from menses for \\> 1 year (females only)\n* ELIGIBILITY TO PROCEED WITH PERIPHERAL BLOOD MONONUCLEAR COLLECTION (PBMC) COLLECTION\n* Research participant must not require more than 0.1mg\u002Fkg\u002Fday total dose (0.03mg\u002Fkg\u002Fdose three times per day, max of 6mg\u002Fday) of Dexamethasone on the day of peripheral blood mononuclear cell (PBMC) collection\n* Research participant must have appropriate venous access\n* At least 2 weeks must have elapsed since the research participant received his\u002Fher last dose of prior targeted agents, chemotherapy or radiation\n* Note: If a research participant weighs less than 50kgs, the study team should provide the Donor Apheresis Center (DAC) with the participant's current weight so that institutional guidelines can be followed\n* ELIGIBILITY TO PROCEED WITH INDWELLING CENTRAL NERVOUS SYSTEM (CNS) CATHETER PLACEMENT\n* Serum creatinine \\\u003C 1.6 mg\u002FdL\n* White blood cell (WBC) \\>= 2,000\u002FdL\n* Absolute neutrophil count (ANC) \\>= 1,000\n* Platelets \\> 50,000\u002FdL\n* International normalized ratio =\\\u003C 1.3\n* Bilirubin \\\u003C 1.5 mg\u002FdL\n* Alanine transferase (ALT) and aspartate transaminase (AST) \\\u003C 2 x upper limits of normal\n* KPS \\>= 60% except for loss of mobility due to disease involvement; e.g., confinement to a wheelchair due to spinal cord compression\n* Second-line radiation therapy (post-leukapheresis) completed at least 4 weeks prior to surgical resection or biopsy\u002Fcatheter placement\n* ELIGIBILITY TO PROCEED WITH LYMPHODEPLETION\n* Pulmonary: Research participant does not require supplemental oxygen to keep saturation greater than 95% and\u002For does not have presence of any radiographic abnormalities on chest x-ray that are progressive\n* Cardiac: Research participant does not require pressor support and\u002For does not have symptomatic cardiac arrhythmias\n* Active infection: Research participant does not have a fever exceeding 38.5 degree celsius; there is an absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to CAR T cell infusion and\u002For there aren't any indications of meningitis\n* Hepatic: Research participant serum total bilirubin or transaminases does not exceed 2 x normal limit\n* Renal: Research participant serum creatinine \\\u003C 1.8 mg\u002FdL\n* Neurologic: Research participant does not have uncontrolled seizure activity following surgery prior to starting lymphodepletion\n* ELIGIBILITY TO PROCEED WITH EACH CAR T CELL INFUSION\n* Research participant has a released cryopreserved T cell product\n* Research participant does not require supplemental oxygen to keep saturation greater than 95% and\u002For does not have presence of any radiographic abnormalities on chest x-ray that are progressive\n* Research participant does not require pressor support and\u002For does not have symptomatic cardiac arrhythmias\n* Research participant does not have a fever exceeding 38.5 degree celsius; there is an absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to T cell infusion and\u002For there aren't any indications of meningitis\n* Research participant serum total bilirubin or transaminases does not exceed 2 x normal limit\n* Research participant serum creatinine \\\u003C 1.8 mg\u002FdL\n* Research participant does not have uncontrolled seizure activity\n* Research participant platelet count must be \\>= 50,000. However, if platelet level is between 25,000-49,000, then T-cell infusion may proceed after platelet transfusion is given and the post transfusion platelet count is \\>= 50,000\n* Research participants must not require more than 0.1mg\u002Fkg\u002Fday total dose (0.03mg\u002Fkg\u002Fdose three times per day, max of 6mg\u002Fday) of dexamethasone during CAR T cell therapy\n* Wash-out requirements:\n\n  * At least 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen;\n  * At least 23 days since the completion of temozolomide and\u002For 4 weeks for any other non-nitrosourea-containing cytotoxic chemotherapy regimen. If a patient's most recent treatment was with a targeted agent only, and s\u002Fhe has recovered from any toxicity of this targeted agent, then a waiting period of only 2 weeks is needed from the last dose\n  * For bevacizumab the wash out period of at least 4 weeks is required before starting study treatment\n\nExclusion Criteria:\n\n* Pulmonary: Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks\n* Cardiac: Research participant requires pressor support and\u002For has symptomatic cardiac arrhythmias\n* Renal: Research participant requires dialysis\n* Neurologic: Research participant has uncontrolled seizure activity and\u002For clinically evident progressive encephalopathy\n* Failure of research participant to understand the basic elements of the protocol and\u002For the risks\u002Fbenefits of participating in this phase I study. A legal guardian may substitute for the research participant\n* Research participant with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the study team deems it unwise to enter the research participant on protocol shall be ineligible\n* Research participant with any other active malignancies\n* Research participant being treated for severe infection or recovering from major surgery is ineligible until recovery is deemed complete by the study team\n* Research participant with any uncontrolled illness including ongoing or active infection. Research participant with known active hepatitis B or C infection; research participant with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections\n* Research participant who has confirmed HIV positivity within 4 weeks of enrollment\n* Females only: Pregnant or breastfeeding\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","4 Years","25 Years",{"count":291,"type":20},18,[23],"This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to treatment (refractory). Cellular immunotherapy (IL13(EQ)BBzeta\u002FCD19t+ T cells) are brain-tumor specific cells that may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many patients with brain tumor respond to treatment, but then the tumor starts to grow again. Giving chemotherapy in combination with cellular immunotherapy may kill more tumor cells and improve the outcome of treatment.",[27,295,296],"Recurrent Malignant Brain Neoplasm","Refractory Malignant Brain Neoplasm","2026-03-03",{"date":299,"type":33},"2026-03-05",{"date":301,"type":33},"2020-12-04",{"date":303,"type":20},"2027-02-24",{"name":305,"class":40},"City of Hope Medical Center",3,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":41},"100526280","phase-2-post-operative-dosing-of-dexamethasone-in-patients-with-brain-tumors-after-a-craniotomy-pods-trial-100526280","NCT06132685","Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)","Inclusion Criteria:\n\n* Patients with radiographic findings consistent with either HGG, LGG, Meningioma, or brain metastasis\n* Age equal to or above 18\n\nExclusion Criteria:\n\n* Known hypothalamic-pituitary-adrenal (HPA) axis dysfunction\n* Tumor causing compression of the sella or pituitary dysfunction\n* Known immunodeficiency - including but not limited to severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), lymphocytopenia\n* Taking immunosuppressive drugs - including but not limited to methotrexate, mycophenolate, rapamycin, tacrolimus, adalimumab, infliximab. Greater than two weeks of recent daily corticosteroid use or the use of corticosteroids equivalent to \\> 85 mg of dexamethasone in the last month\n* Current lymphoma or leukemia\n* History of solid organ transplant\n* Minors \\\u003C 18\n* Pregnant women\n* History of cerebrovascular accident leading to neurologic deficit",{"count":315,"type":20},200,[24],"This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also works to treat other conditions by reducing swelling and redness. Tapering doses dexamethasone may decrease steroid side effects without increasing the risk of edema in patients with brain tumors after a craniotomy.",[319,320,27,321],"Low Grade Glioma","Malignant Brain Glioma","Meningioma","2026-02-06",{"date":324,"type":33},"2026-02-10",{"date":326,"type":33},"2025-01-09",{"date":328,"type":20},"2028-07-30",{"name":330,"class":40},"Emory University",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":41},"100566052","phase-1-zr-89-crefmirlimab-berdoxam-and-immuno-positron-emission-tomography-for-the-imaging-of-patients-with-resectable-brain-tumors-100566052","NCT06650163","Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors","Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors","Inclusion Criteria:\n\n* Male or female \\>= 18 years of age\n* Documentation of a diagnosis of brain tumor including brain metastases, any grade of gliomas and meningiomas\n* The participant is scheduled for standard of care surgical tumor resection\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial\n\nExclusion Criteria:\n\n* Male or female \\\u003C 18 years of age\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data\n* Not medically cleared for surgery\n* Individuals who cannot tolerate MRI scan or PET\u002FCT scan\n* Pregnant or breast-feeding women\n* Serum creatinine OR measured or calculated creatinine clearance (Glomerular filtration rate \\[GFR\\] can be use in place of creatinine or creatinine clearance \\[CrCl\\]) =\\\u003C 1.5 X institutional upper limit of normal (ULN) OR \\>= 60mL\u002Fmin for subjects with creatinine levels \\> 1.5 X institutional ULN\n\n  * Creatinine clearance should be calculated per institutional standard\n* Serum total bilirubin: =\\\u003C 1.5 X institutional ULN OR direct bilirubin =\\\u003C institutional ULN for subjects with total bilirubin levels \\> 1.5 institutional ULN\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\\u003C 2.5 X institutional ULN OR =\\\u003C 5 X institutional ULN for subjects with Gilberts syndrome\n* Albumin \\>= 2.5 mg\u002FdL\n* Patients with splenic dysfunction or post splenectomy\n* Any abnormalities that would be a contraindication to gadolinium-based contrast agent",{"count":339,"type":20},20,[23],"This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presence and change in CD8 positive (+) tumor infiltrating lymphocytes (TIL) cells. Identifying the presence and changes in CD8+ cells can be challenging, particularly for participants with central nervous system (CNS) tumors, and usually requires invasive procedures such as repeat tissue biopsies, which may not accurately represent the immune status of the entire tumor. Zr-89 crefmirlimab berdoxam is known as a radioimmunoconjugate which consists of a radiolabeled anti-CD8+ minibody whose uptake can be imaged with PET. Upon administration, Zr 89 crefmirlimab berdoxam specifically targets and binds to the CD8+ cells. This enables PET imaging and may detect CD8+ T-cell distribution and activity and may help determine the patient's response to cancer immunotherapeutic agents more accurately. Giving Zr-89 crefmirlimab berdoxam along with undergoing immuno-PET imaging may work better at identifying immune cell activity in patients with resectable brain tumors.",[343,27,321,344],"Glioma","Metastatic Malignant Neoplasm in the Brain","2026-02-03",{"date":347,"type":33},"2026-02-05",{"date":349,"type":33},"2024-12-05",{"date":351,"type":20},"2028-01-31",{"name":353,"class":40},"Jonsson Comprehensive Cancer Center",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":41},"100619012","advanced-magnetic-resonance-imaging-for-the-identification-of-recurrent-brain-tumors-and-radiation-necrosis-100619012","NCT07339085","Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis","Advanced Dual-Nuclei MRI for Differentiation of Recurrent Brain Metastases and Radiation Necrosis","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Diagnosed with metastatic brain tumor\n* AIM 1: Scheduled for surgical resection or tissue biopsy +\u002F- laser interstitial thermal therapy (LITT)\n* AIM 2: Scheduled for SRS treatment\n\nExclusion Criteria:\n\n* Patients with contraindications to MRI, severe renal impairment\n* Patients with evidence of disseminated leptomeningeal disease",{"count":362,"type":20},42,[54],"This clinical trial studies whether advanced magnetic resonance imaging (MRI) techniques, including diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, can be used to identify the difference between brain tumors that come back after a period of improvement (recurrent) and treatment-related tissue damage (radiation necrosis \\[RN\\]). Radiation therapy is often used in the treatment of brain tumors. Radiation treatment response can be difficult to assess and is usually done using conventional MRI, which uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. Current imaging techniques have a limited ability to identify the difference between recurrent brain tumor and RN due to their similar appearance on conventional MRI and overlapping clinical presentation. This makes it hard for doctors to plan the best way to treat these tumors. DR-CSI is a new MRI technique with the potential to detect microscopic tissue components with different characteristics. Sodium imaging is an MRI technique that estimates the total sodium concentration in the obtained images. It may be able to identify the small structures within the tissue of brain tumors. Advanced MRI techniques like DR-CSI and sodium imaging may be effective in identifying the difference between recurrent brain tumors and RN.",[27,344],"2026-01-14",{"date":368,"type":33},"2026-01-15",{"date":370,"type":33},"2025-08-28",{"date":372,"type":20},"2030-07-30",{"name":353,"class":40},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":41},"100606369","educational-tools-for-the-improvement-of-early-advance-care-planning-in-adolescents-and-young-adults-with-advanced-solid-tumors-and-high-grade-brain-tumors-100606369","NCT07174661","Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors","Empowerment Through Preparedness: Improving Advance Care Planning (ACP) in Adolescents and Young Adults (AYAs) With Advanced Solid Malignancies and High-Grade Brain Tumors","Inclusion Criteria:\n\n* Age 18-39 at initial cancer diagnosis\n\n  * Patient \\\u003C18 years of age are not included in this pilot as Mayo Clinic in Arizona (MCA) does not treat pediatric patients\n* Recently diagnosed (defined as 12 months or less from initial diagnosis or advance stage relapse) with either a stage III\u002FIV solid malignancy or high-grade brain tumor. This includes patients who have stage III\u002FIV recurrence of previously stage I\u002FII solid malignancy\n* Actively receiving primary oncologic care at Mayo Clinic Arizona\n* Able to read, understand, and speak English\n* Those who have completed prior advance directive documents are still eligible to participate.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 39 at initial cancer diagnosis\n* Diagnosed with stage I\u002FII solid malignancy, low-grade brain tumor, or hematologic malignancy\n* Not receiving primary oncologic care at Mayo Clinic Arizona\n* Unable to read, understand, and speak English\n* Patients \\> 12 months from initial diagnosis or advanced stage relapses, in survivorship or on hospice\n* No internet or computer\u002Fsmart phone access",{"count":382,"type":20},50,[54],"This clinical trial studies whether educational tools work to improve early advance care planning (ACP) in adolescents and young adults (AYAs) with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and high-grade brain tumors. The incidence of AYA cancers is on the rise with approximately 90,000 new diagnoses yearly in the United States. Cancer remains the leading cause of disease-related death among AYAs, which could be due to patients having more advanced disease at presentation. It is recommended that AYAs begin ACP conversations at the start of treatment. ACP includes clarifying goals of care, discussions about end-of-life preferences, and completing a legal document that states the treatment or care a person wishes to receive or not receive if they become unable to make medical decisions (advance directive). The educational tools in this study include an early ACP educational video featuring AYAs with cancer and an ACP appointment geared for AYAs. Patients can access and watch the educational video at home prior to their scheduled ACP appointment. During the ACP appointment, a tailored ACP guide made specifically for AYAs is reviewed and questions regarding ACP are answered. This may help to introduce the importance of key ACP concepts, which may improve early ACP in AYAs with advanced solid tumors and high-grade brain tumors.",[386,27,387],"Advanced Malignant Solid Neoplasm","Recurrent Advanced Malignant Solid Neoplasm","2025-12-11",{"date":390,"type":33},"2025-12-18",{"date":392,"type":33},"2025-09-02",{"date":394,"type":20},"2027-06-30",{"name":69,"class":40},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":21,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":41},"100545115","phase-2-remote-cognitive-assessment-and-wearable-device-while-assessing-the-impact-of-metformin-in-patients-with-history-of-cranial-radiation-therapy-100545115","NCT06377696","Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy","Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of brain tumor requiring cranial radiation treatment NOTE: Patient may be enrolled during or up to 5 years after completion of cranial radiation administered for treatment of primary or metastatic intracranial tumor\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 70\n* Expected survival ≥ 6 months in the opinion of treatment team\n* Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations\n* The following laboratory values obtained ≤ 30 days prior to registration:\n\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN \\[≤ 5 x upper limit normal (ULN) for patients with baseline liver disease\\]\n* Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only\n* Ability to complete cognitive assessments and questionnaires by themselves or with assistance\n\nExclusion Criteria:\n\n* Uncontrolled and\u002For intercurrent illness or other condition which limits safety of or compliance with study proceedings\n* Pregnant or nursing, imprisoned, or lacking capacity for understanding\n* Unable to swallow tablets or at risk for impaired absorption of oral medication\n* Currently taking the study agent (i.e., metformin), and cannot safely discontinue if randomized to the control group (Group B)\n* Known hypersensitivity or allergy to metformin\n* Current use of resveratrol, CoQ10 (coenzyme Q10), coconut oil\u002Fother medium chain triglyceride-containing (e.g., Axona) supplements, or curcumin and unwilling to discontinue prior to registration and remain off these agents for study duration\n* Unable to read and speak English. Note: English doses not to need to be primary language",{"count":404,"type":20},100,[24],"This phase III trial evaluates whether patient care can be done remotely for patients having cranial (skull) radiation or who have previously had cranial radiation. In addition, this trial compares study outcomes between patients who get metformin and those who do not. Cranial radiation, an essential component of brain tumor treatment, can result in significant negative effects on cognitive (the ability to clearly think, learn, and remember) function. Wearable devices have been used in the field of neurology for seizure detection and assessment of patients with movement disorders. Wearable device technology has also been implemented for remote monitoring of cancer patients and for cancer clinical trials. Metformin is the active ingredient in a drug used to treat type 2 diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. Use of metformin may reduce risk of cognitive decline following radiation therapy within the skull (intracranial). These effects may be further strengthen by addition of device-based physical activity promotion. Mayo Test Drive is a web-based platform for remote self-administered cognitive assessment. Using Mayo Test Drive may help determine whether patient care can be done remotely, while simultaneously evaluating benefits of health promotion through use of a wearable watch device and metformin in preventing radiation-related cognitive decline.",[27],"2025-08-29",{"date":392,"type":33},{"date":411,"type":33},"2024-05-31",{"date":413,"type":20},"2027-05-01",{"name":69,"class":40},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":21,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":41},"100335627","phase-2-feasibility-of-fmiso-in-brain-tumors-100335627","NCT03649880","Feasibility of FMISO in Brain Tumors","Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors","Inclusion Criteria:\n\n* Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor.\n* Able to provide informed written consent and\u002For acceptable surrogate capable of providing consent on the patient's behalf.\n* Legally authorized representative (LAR)-signed informed consent and assent obtained for those subjects identified as decisionally impaired\n* Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2\u002Ffluid attenuated inversion recovery (FLAIR) MR imaging.\n* Karnofsky performance score \\> 60 or Eastern Cooperative Oncology Group (ECOG) \\\u003C 3 as assessed by referring clinician.\n* Planning to undergo or previously received therapeutic intervention for the intracranial tumor.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.\n\n  * Claustrophobia.\n  * Weight greater than modality maximum capacity.\n  * Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \\& Science University (OHSU) Department of Radiology guidelines (including but not limited to cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants).\n  * Sickle cell disease.\n  * Reduced renal function, as determined by glomerular filtration rate (GFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m\\^2 based on a serum creatinine level obtained per OHSU Department of Radiology and Advanced Imaging Research Center (AIRC) clinical criteria.\n  * History of allergic reactions attributed to compounds of similar chemical or biologic composition to FMISO. An allergic reaction to nitroimidazoles is highly unlikely.\n  * Unsure of pregnancy status as assessed by Department of Radiology and AIRC guidelines.\n  * Subjects for whom supplemental oxygen could be harmful such as people with potential for hypoventilation (end-stage COPD, OSA on CPAP\u002FBi-PAP, etc).\n  * Subjects with a relative contraindication to supplemental oxygen administration will not be provided oxygen but may still participate in the study.\n* Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject (i.e., plans for hospice or end of life care).\n* Poor peripheral intravenous access evaluated by patient history.\n* Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric\u002Fsocial situations which might impact the endpoint of the study or limit compliance with study requirements.",{"count":382,"type":20},[24],"This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)\u002Fmagnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET\u002FMRI imaging produces images of the brain and how the body functions. FMISO PET\u002FMRI may help investigators see how much oxygen is getting in the brain tumors.",[27],"2025-03-20",{"date":428,"type":33},"2025-03-25",{"date":430,"type":33},"2019-06-01",{"date":432,"type":20},"2030-01-31",{"name":434,"class":40},"OHSU Knight Cancer Institute"]